论文部分内容阅读
目的:对克龄蒙联合坤泰胶囊用于卵巢早衰的临床安全性进行观察分析。方法:选取惠州市第一妇幼保健院在2013年1月-2013年12月收治的卵巢早衰患者60例作为研究对象,随机均分为两组,实验组以克龄蒙联合坤泰胶囊治疗,对照组单纯采用克龄蒙治疗,对比两组疗效和不良反应发生情况。结果:两组治疗后FSH、LH、E2三项激素水平均显著改善,但实验组变化幅度大于对照组;实验组治疗有效率为90%,不良反应发生率为6.7%;对照组有效率为76.7%,不良反应发生率为20%,组间比较,差异均具有统计学意义(P<0.05)。结论:克龄蒙联合坤泰胶囊治疗卵巢早衰,疗效显著,且安全性相对较高,是一种具有一定优势的治疗方法。
OBJECTIVE: To observe and analyze the clinical safety of Kelong Capsule combined with Quentin in the treatment of premature ovarian failure. Methods: Sixty patients with premature ovarian failure who were admitted to the First Maternal and Child Health Hospital of Huizhou City from January 2013 to December 2013 were selected and randomly divided into two groups. The experimental group was treated with combination of Kumuren and kuntai capsule, The control group was treated with jinglengmeng alone, comparing the two groups efficacy and adverse reactions. Results: The levels of FSH, LH and E2 in both groups were significantly improved after treatment, but the changes in the experimental group were greater than those in the control group. The effective rate was 90% in the experimental group and 6.7% in the adverse reaction group. The effective rate in the control group was 76.7%, the incidence of adverse reactions was 20%, between groups, the differences were statistically significant (P <0.05). Conclusion: Kelong Capsule combination of Kun Tai treatment of premature ovarian failure, significant effect, and the safety is relatively high, is a kind of certain advantages of the treatment.